Belatacept + Calcineurin Inhibitor
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function, Kidney Transplant
Trial Timeline
Jun 1, 2013 → Jun 1, 2017
NCT ID
NCT01837043About Belatacept + Calcineurin Inhibitor
Belatacept + Calcineurin Inhibitor is a phase 2 stage product being developed by Bristol Myers Squibb for Delayed Graft Function. The current trial status is unknown. This product is registered under clinical trial identifier NCT01837043. Target conditions include Delayed Graft Function, Kidney Transplant.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01837043 | Phase 2 | UNKNOWN |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 32 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Desflurane + Propofol | Baxter | Approved | 82 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |